Latest news


First patient enrolled in the fimaChem pivotal RELEASE study

Posted on May 23, 2019

Oslo (Norway), 23 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced first patient enrolled in the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has the potential of accelerated/conditional marketing approval […]

Notice of Annual General Meeting 2019

Posted on May 8, 2019

Oslo, Norway 8 May 2019 – The shareholders of PCI Biotech Holding ASA are invited to attend the Annual General Meeting 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday May 29, 10am CEST (local time). Venue: Jónas Einarsson Auditorium (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo, Norway. The notice […]

First quarter 2019 results

Posted on May 8, 2019

Oslo (Norway), 8 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its first quarter 2019 result. Please find enclosed the report and presentation. First sites for the pivotal fimaCHEM “RELEASE” study open for enrolment and successful translation of fimaVACC into man. Final confirmation of safety with two treatments was […]